
Access to Labor After Cesarean Limited in Most US Counties
Fewer than 16% of US counties between 2016 and 2021 were home to a hospital offering labor after cesarean (LAC) services or the planned attempt to deliver vaginally by a person who previously had a cesarean.
METHODOLOGY:
While recent clinical guidelines encourage hospitals and clinicians to enable patients to undergo a vaginal birth even after a prior cesarean, researchers set out to find out the availability of these services using the proxy of labor after cesarean (LAC) delivery, which is associated with a decreased maternal morbidity and the risk of complications in future pregnancies.
In this cross-sectional study, researchers examined hospitals that offered LAC services and the county in which the facility was located.
This was determined by looking at county-level rates of LAC, vaginal births after cesarean, and prior cesarean births.
TAKEAWAY:
Residents living in metropolitan counties had an access rate of 30.5% compared with 7.4% in metro-adjacent and 6.8% in metro-nonadjacent counties.
In counties with only hospital-based obstetric services, 30.9% had access to LAC.
Access to LAC did not vary across years, but regional differences were noted, with more prevalent access in the Northeast and West regions.
IN PRACTICE:
'Although the American College of Obstetricians and Gynecologists states is a reasonable option for many individuals with a prior cesarean delivery, many birthing people may not be able to access LAC due to a lack of local availability,' the authors of the study wrote.
SOURCE:
This study was led by Brittany L. Ranchoff, PhD, MPH, of the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Health Care Institute in Boston. It was published online on August 8, 2025, in JAMA Network Open.
LIMITATIONS:
The quality of items on birth certificates could potentially lead to misclassification when defining counties that offer LAC services. Despite the observed increases in the rates of vaginal birth after cesarean, the limited access to LAC suggested that these services may have become concentrated among fewer hospitals or clinicians.
DISCLOSURES:
This study did not report any specific funding. Two authors reported receiving grants or funding, while another author disclosed receiving contracts outside the submitted work.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Electrophysiology Market worth US$21.72 billion by 2030 with 11.6% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Electrophysiology Market, valued at US$11.41 billion in 2024, stood at US$12.55 billion in 2025 and is projected to advance at a resilient CAGR of 11.6% from 2025 to 2030, culminating in a forecasted valuation of US$21.72 billion by the end of the period. The rise of the electrophysiology market can be attributed to several drivers: the increasing prevalence of cardiovascular diseases, including arrhythmias and atrial fibrillation; patients and healthcare providers are increasingly favoring minimally invasive procedures over traditional surgical interventions; electrophysiological techniques, such as catheter ablation, offer less invasive options for treating certain cardiac arrhythmias; and government support and initiatives aimed at improving healthcare infrastructure and funding research and development in electrophysiology also contribute to market growth. Download PDF Brochure: Browse in-depth TOC on "Electrophysiology Market" 322 - Tables62 - Figures330 - Pages By product, in 2024, electrophysiology ablation catheters are expected to be the leading segment in the medical device market. This anticipated growth is largely driven by the rising global prevalence of atrial fibrillation (AF) and various cardiac arrhythmias, which has increased the demand for minimally invasive ablation techniques. Recent technological advancements in catheter design, such as the introduction of contact force-sensing mechanisms, irrigated-tip designs, and high-power short-duration (HPSD) ablation systems, have greatly enhanced procedural safety, precision, and clinical outcomes. These innovations are contributing to wider acceptance and increased utilization of these catheters within the medical community. By indication, the electrophysiology market, divided by medical indications, includes segments such as atrial fibrillation, atrial flutter, and atrioventricular nodal reentry tachycardia. Atrial flutter, characterized by rapid heartbeats from the atria, is increasingly common, especially among the elderly, due to age-related cardiac changes. This rising prevalence has created a demand for advanced diagnosis and treatment options tailored to atrial flutter. Innovations in catheter ablation, advanced imaging techniques, and new pharmacological therapies reflect the urgency for effective arrhythmia management in an aging population. By geography, in 2024, North America, primarily the US and Canada, is set for significant growth in the medical technology market. The region is a global leader in medical innovations, especially in electrophysiology, often adopting breakthroughs ahead of others. With some of the highest healthcare spending globally, the US influences the uptake of advanced medical technologies, enhancing patient outcomes and operational efficiency. Strong A investment in research and development fosters innovation and creates a robust marketplace for new products and services, solidifying North America's role as a key driver of growth in the medical technology sector. Request Sample Pages : As of 2024, prominent players in the electrophysiology market are Johnson & Johnson Services, Inc. (US), Abbott (US), Medtronic (Ireland), Koninklijke Philips N.V. (Netherlands), GE Healthcare (US), Boston Scientific Corporation (US), Japan Lifeline Co., Ltd (Japan), Stereotaxis, Inc. (US), MicroPort Scientific Corporation (China), and BIOTRONIK (Germany). Abbott (US): Abbott Laboratories is a comprehensive healthcare company that operates across diverse sectors, including pharmaceuticals, medical devices, diagnostics, and nutrition. The company has established a significant presence in electrophysiology, particularly in the development of advanced medical devices for cardiac electrophysiology procedures. Abbott's portfolio in this specialized market includes sophisticated mapping systems, electrophysiology catheters, and related technologies designed for the precise diagnosis and management of cardiac arrhythmias. Furthermore, Abbott is likely engaged in ongoing research and development initiatives aimed at innovating and enhancing electrophysiological technologies to improve patient outcomes and procedural efficiencies. Koninklijke Philips N.V. (Netherlands) Koninklijke Philips N.V. Philips, a Netherlands-based multinational company, is a significant player in the healthcare sector, particularly within medical technology. The company develops an extensive range of products that enhance capabilities in cardiology, patient monitoring, diagnostic imaging, and electrophysiology. In the electrophysiology domain, Philips offers advanced solutions aimed at the identification and management of cardiac arrhythmias. This product suite includes high-precision imaging technologies, advanced mapping systems, and specialized electrophysiology catheters, all essential tools utilized by cardiology professionals. Key offerings include the EP WorkMate system, which serves as a comprehensive electrophysiology recording and reporting platform, facilitating efficient data capture and analysis during procedures. Additionally, Philips has introduced state-of-the-art X-ray imaging systems designed for enhanced visualization during electrophysiological interventions. The EP Navigator and EP-XT Mapping system are also part of their innovative portfolio, providing clinicians with advanced three-dimensional mapping capabilities that improve procedural accuracy and patient outcomes. For more information, Inquire Now! Related Reports: Defibrillator Market Cardiac Monitoring & Cardiac Rhythm Management Devices Market Ablation Technology Market Catheters Market Digital X-ray Market Get access to the latest updates on Electrophysiology Companies and Electrophysiology Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets
Yahoo
an hour ago
- Yahoo
UK pharmacist says Eli Lilly's Mounjaro price hike a 'shock'
Eli Lilly will increase the UK list price of its blockbuster drug Mounjaro (tirzepatide) amid pressure from US President Donald Trump for drugmakers to hike prices outside the US. In the UK, Mounjaro is indicated for the treatment of type 2 diabetes (T2D) and weight loss. In the US, the name Mounjaro is only used for T2D while Eli Lilly markets tirzepatide for weight loss in the US under the brand name Zepbound. Mounjaro generated global sales of $5.2bn in Q2 alone, up 68% from the same period last year. In a statement sent to Pharmaceutical Technology, Eli Lilly said that the price changes will not affect the drug's availability on the UK's National Health Service (NHS), saying it had 'reached an agreement with the healthcare system to ensure continued supply and patient access'. The drugmaker added: 'While Lilly does not determine the prices that private healthcare providers set, we are working with them to maintain patient access.' Mounjaro's current list price in the UK ranges from £92 (approximately $125) to £122 a month, depending on the dose, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on 1 September. GlobalData said in a research note: "For the UK, this latest step by Eli Lilly may potentially be seen as the start of a wave of higher medicine prices than the country has been accustomed to in recent years. Heading into 2026, [we] may expect to see a narrowing of the gap between the US and UK (and potentially between the US and EU) pricing for some new medicines." When it was rolled out in the UK in February 2024, Eli Lilly agreed to a list price 'significantly below' that of other competitor European markets to stop delays in the availability of the medicine to diabetes patients through the NHS. A pharmacist in London, who wishes to remain anonymous, told Pharmaceutical Technology: 'I was shocked today with the email that we pharmacists received about Mounjaro's price increase. We have so many patients on this medicine, and now half of them will be really struggling to pay for it. 'I already have some of them asking me for discounts and with the increase, that will be impossible. I feel really sad for patients who use the injection to control their blood sugar levels and now they might not be able to do so. Why did the manufacturer wait so long to make this price change?' Dr Leyla Hannbeck, CEO of the Independent Pharmacies Association (IPA), said: "We are shocked and very disappointed," while reacting to the news. Lilly said the changes, which follow a pricing review, 'address pricing inconsistencies compared to other developed countries, including in Europe'. International pricing pressures also contributed to the mark-up, according to the company. President Trump has been pressuring US drugmakers to cut prices of prescription medicines in the country, which cost around three times more than identical counterparts in other developed nations. He famously relayed a phone call he took from a friend in the UK, who complained about a 'damn fat drug' that cost $88 in London but $1,300 in New York. The stark difference in costs for weight loss drugs was one of the factors that led Trump to introduce the Most Favoured Nation (MFN) policy, a framework that would tie US drug prices to the lowest prices in other developed countries. Amid pushback from the industry, Trump sent letters to leading pharma companies, including Eli Lilly, calling on them to take more steps to lower prices. '[Eli] Lilly agrees with the policy objective expressed in the executive order that research costs for breakthrough medicines should be shared more fairly across developed countries. However, a Most Favoured Nation approach is not the answer to help patient affordability,' Eli Lilly told Pharmaceutical Technology. "IPA calls on the other weight-loss manufacturers to hold their nerves and hold their prices. The British market for weight-loss jabs will is only set to grow, but it will only achieve that growth if treatment remains affordable to the average patient," Dr Hannbeck commented. "UK pharmacist says Eli Lilly's Mounjaro price hike a 'shock'" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
an hour ago
- Yahoo
IKS Health Wins Google Cloud Award for its Care Enablement Platform for Augmenting Human Expertise with AI
DALLAS, August 15, 2025--(BUSINESS WIRE)--IKS Health, a global leader in care enablement solutions supporting clinicians, staff, and patients at every step of the care journey, is proud to announce its Care Enablement Platform has won a Google Cloud 2025 DORA Award for "Augmenting Human Expertise with AI." IKS Health's Care Enablement Platform is a technology-powered ecosystem that combines advanced automation, data intelligence, and human expertise to offload administrative, clinical, and operational tasks. Its unique human + AI model is a seamless fusion of intelligent automation with domain-expert intervention to ensure accuracy and empathy. "Our goal is to alleviate the increasing administrative and operational burdens faced by clinicians, and our team is proud to achieve recognition from Google Cloud for our AI-human hybrid model that delivers superior accuracy, empathy, and trust compared to standalone automation," said Vijay Venkatesan, Chief Technology Officer, IKS Health. Google Cloud's DORA Awards celebrate the technical excellence and elite performance that is possible with software development and delivery. The IKS Health AI + human model accelerates delivery, cuts delays, reduces errors, and minimizes downtime, driving faster innovation and more reliable operations. "We are honored to receive such a prestigious award from Google Cloud for our advanced work in the 'Augmenting Human Expertise with AI' category," said Sachin K. Gupta, Founder and Global CEO, IKS Health. "Validation of our goal to create a platform-based solution that healthcare organizations can rely on to scale operations fuels us to continue the work of transforming healthcare so that clinicians can focus on their core work." About IKS Health IKS Health takes on the chores of healthcare — spanning administrative, clinical, and operational burdens — so that clinicians can focus on their core purpose: delivering great care. Combining pragmatic technology and dedicated experts, IKS Health enables stronger, financially sustainable enterprises. IKS Health's Care Enablement Platform delivers data-driven value and expertise across the care journey, and IKS Health is a partner for clinician enterprises looking to effectively scale, improve quality, and achieve cost savings through forward-thinking solutions. Founded in 2006, IKS Health's global workforce supports large health systems across the United States. For more information on IKS Health and its solutions, please visit Inventurus Knowledge Solutions Limited is listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE). {Scrip codes: NSE - IKS and BSE - 544309} View source version on Contacts MEDIA CONTACT - IKS HEALTH Jill Gross, Director of Public Relationspress@